Skip to main content
SpringerLink
Log in

A value-based benefit design (VBBD) that decreased copayment by almost 50% for diabetes drugs significantly improved medication compliance

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. MedImpact, Health Alliance Medical Plans.MedImpact Study Highlights Effects of Value-Based Benefit Design on Adherence to Diabetes Medications. Media Release: 3 Jun 2009. Available from: URL: http://www.businesswire.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

A value-based benefit design (VBBD) that decreased copayment by almost 50% for diabetes drugs significantly improved medication compliance. Pharmacoecon. Outcomes News 580, 9 (2009). https://doi.org/10.2165/00151234-200905800-00023

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905800-00023

Keywords

Search

Navigation